Related Experiment Video

Updated: Aug 14, 2026

Isolation of Functional Cardiac Immune Cells
07:26

Isolation of Functional Cardiac Immune Cells

Published on: December 5, 2011

[Cytokines and heart failure]

G Baumgarten1, C Grohe, A Hoeft

  • 1Klinik für Anästhesiologie und spezilae Intensivmedizin, Rheinischen Friedrich-Wilhelms-Universität, Bonn. Georg.Baumgarten@ukb.uni-bonn.de

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
|April 21, 2004
PubMed

Insights

Cytokines play a key role in chronic heart failure (CHF) pathogenesis, impacting left ventricular function. Anti-inflammatory strategies targeting cytokines are crucial for future CHF treatment development.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Context:

  • Chronic heart failure (CHF) is a leading cause of mortality and morbidity.
  • Existing hypotheses on CHF pathogenesis lack comprehensive explanations.
  • Cytokines are implicated in CHF development and progression.

Purpose:

  • To review experimental and clinical evidence on cytokines in CHF.
  • To discuss pharmacologic interventions modulating cytokine expression.
  • To highlight the potential of anti-inflammatory approaches for CHF treatment.

Summary:

  • Cytokines are expressed during CHF and significantly depress left ventricular function.
  • ACE-inhibitors, beta-blockers, and angiotensin type 1 antagonists can modulate cytokine expression.
  • Research indicates a strong link between cytokine activity and CHF characteristics.

Impact:

  • Findings underscore the importance of understanding cytokine roles in CHF.
  • Suggests that anti-inflammatory therapies represent a promising avenue for CHF management.
  • Emphasizes the need for further research into cytokine-targeted treatments for heart failure.

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology10:41

Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology

Published on: January 23, 2021

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.